

Letter to the editor:

THE BODY-ON-A-CHIP CONCEPT: POSSIBILITIES AND LIMITATIONS

Raymond Reif

Leibniz Institut für Arbeitsforschung an der TU Dortmund,
Leibniz Research Centre for Working Environment and Human Factors (IfADo),
Ardeystrasse 67, 44139 Dortmund, Germany; reif@ifado.de

Dear Editor,

Recently, Frey et al. (2014) have established a reconfigurable microfluidic platform to study multi-tissue interactions. This platform contains multiple spheroids of different cell types in hanging drops. The hanging drops are connected by microfluidic networks. The path of the liquid flow through the hanging drops is precisely controlled and offers the possibility to perfuse them either sequently or parallelized. For example culture media may first pass a hanging drop with a liver spheroid and subsequently pass kidney, heart, bone marrow, or neuronal tissues (Frey et al., 2014). Currently, many groups work on the optimization of ‘body-on-a-chip’ systems (Kelm and Marchan, 2014; Sung et al., 2014; Williamson et al., 2013). Currently, ‘organ-on-a-chip’ concepts are developed for many tissues including heart (Zweigerdt et al., 2014; Agarwal et al., 2013), kidney (Jang et al., 2013), lung (Punde et al., 2014; Weis et al., 2013; Huh et al., 2012) and intestine (Esch et al., 2014, 2012). Years before the ‘body-on-a-chip movement’ much work has been invested in the optimization of three dimensional culture systems (Xie et al., 2006; Marquette et al., 2007; De Kock et al., 2011; Teichmann et al., 2014; Ramaiahgari et al., 2014). Among the easiest and most efficient methods of 3D culture are the collagen sandwich technique, where cells are cultivated between two layers of soft gel collagen (Schug et al., 2008; 2013; O’Brien, 2006) or cell spheroids which can be generated by hanging drop cultures (Messner et al., 2013; Godoy et al., 2013). Today organotypical in vitro systems are frequently used to study mechanisms of toxicity, particularly in the fields of hepatotoxicity (Schyschka et al., 2013; Rodriques et al., 2013; Watzek et al., 2013; Ilkavets, 2013), nephrotoxicity (Limonciel et al., 2012; Jennings et al., 2012) and developmental toxicity (Bolt, 2013; Balmer et al., 2014; Zimmer et al., 2014; Stern et al., 2014; Krug et al., 2013a, b). These organotypical in vitro systems are now used in ‘body-on-a-chip’ devices if they can be transferred to cell culture microdevices.

Nevertheless, despite of recent progress in ‘body-on-a-chip’ research it is clear that this concept is still in its infancy. For example, the overall quality of the ‘body-on-a-chip’ is limited by the quality of its ‘microorgans’. Although multiple publications claim that three dimensional (3D) culture systems represent higher levels of tissue organization, this is certainly not correct. Correct would be that 3D culture systems represent some aspects of real tissue but many tissue functions are not represented. For example liver microtissues establish bile canaliculi between the hepatocytes. Therefore, these model systems may be used to study excretion of compounds from hepatocytes into bile canaliculi. However, liver microtissues currently do not establish sinusoids, the liver’s microvessels (Hammad et al., 2014). This causes numerous differences to real liver tissue. For example the sinusoidal tissue unit is not correctly established. Liver sinusoidal endothelial cells (LSECs) with Kupffer cells at their luminal and stellate cells at the parenchymal side are responsible for numerous mechanisms in toxicology,

ranging from interactions with circulating immune cells to pathogenesis of liver fibrosis. Obviously, this sinusoidal tissue unit is not correctly recapitulated by the currently available artificial microtissues. Similar critical limitations could be described for microtissues representing other organs. In conclusion, microfluidics offer the prospect to establish complex physiological scenarios under accurately ‘reproducible *in vitro* conditions’. However, the hunt for a ‘body-on-a-chip’ or even an ‘organ-on-a-chip’ that really deserves this name has only just begun.

REFERENCES

- Agarwal A, Goss JA, Cho A, McCain ML, Parker KK. Microfluidic heart on a chip for higher throughput pharmacological studies. *Lab Chip*. 13:3599-608.
- Balmer NV, Klima S, Rempel E, Ivanova VN, Kolde R, Weng MK, et al. From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. *Arch Toxicol*. 2014;88:1451-68.
- Bolt HM. Developmental neurotoxicity testing with human embryonic stem cell-derived *in vitro* systems: the novel FP7 ESNATS tests are available. *Arch Toxicol*. 2013;87:5-6.
- De Kock J, Ceelen L, De Spiegelaere W, Casteleyn C, Claes P, Vanhaecke T, Rogiers V. Simple and quick method for whole-liver decellularization: a novel *in vitro* three-dimensional bioengineering tool? *Arch Toxicol*. 2011;85:607-12.
- Esch MB, Sung JH, Yang J, Yu C, Yu J, March JC, et al. On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic ‘body-on-a-chip’ devices. *Biomed Microdevices*. 2012;14:895-906.
- Esch MB, Mahler GJ, Stokol T, Shuler ML. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. *Lab Chip*. 2014;14:3081-92.
- Frey O, Misun PM, Fluri DA, Hengstler JG, Hierlemann A. Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis. *Nat Commun*. 2014;5:4250.
- Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 2D and 3D *in vitro* systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. *Arch Toxicol*. 2013;87:1315-530.
- Hammad S, Hoehme S, Friebe A, von Recklinghausen I, Othman A, Begher-Tibbe B, et al. Protocols for staining of bile canalicular and sinusoidal networks of human, mouse and pig livers, three-dimensional reconstruction and quantification of tissue microarchitecture by image processing and analysis. *Arch Toxicol*. 2014;88:1161-83.
- Huh D, Leslie DC, Matthews BD, Fraser JP, Jurek S, Hamilton GA, et al. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. *Sci Transl Med*. 2012;4(159):159ra147.
- Ilkavets I. A special issue about hepatotoxicity and hepatocyte *in vitro* systems. *Arch Toxicol*. 2013;87:1313-4.
- Jang KJ, Mehr AP, Hamilton GA, McPartlin LA, Chung S, Suh KY, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. *Integr Biol (Camb)*. 2013;5:1119-29.
- Jennings P, Weiland C, Limonciel A, Bloch KM, Radford R, Aschauer L, et al. Transcriptomic alterations induced by Ochratoxin A in rat and human renal proximal tubular *in vitro* models and comparison to a rat *in vivo* model. *Arch Toxicol*. 2012;86:571-89.
- Kelm JM, Marchan R. Progress in ‘body-on-a-chip’ research. *Arch Toxicol*. 2014;88:1913-4.
- Krug AK, Balmer NV, Matt F, Schönenberger F, Merhof D, Leist M. Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants. *Arch Toxicol*. 2013a;87:2215-31.
- Krug AK, Kolde R, Gaspar JA, Rempel E, Balmer NV, Meganathan K, et al. Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. *Arch Toxicol*. 2013b;87:123-43.
- Limonciel A, Wilmes A, Aschauer L, Radford R, Bloch KM, McMorro T, et al. Oxidative stress induced by potassium bromate exposure results in altered tight junction protein expression in renal proximal tubule cells. *Arch Toxicol*. 2012;86:1741-51.

- Marquette ML, Byerly D, Sognier M. A novel in vitro three-dimensional skeletal muscle model. *In Vitro Cell Dev Biol Anim.* 2007;43:255-63.
- Messner S, Agarkova I, Moritz W, Kelm JM. Multi-cell type human liver microtissues for hepatotoxicity testing. *Arch Toxicol.* 2013;87:209-13.
- O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. *Arch Toxicol.* 2006;80:580-604.
- Punde TH, Wu WH, Lien PC, Chang YL, Kuo PH, Chang MD, et al. A biologically inspired lung-on-a-chip device for the study of protein-induced lung inflammation. *Integr Biol (Camb).* 2014 Dec 8. [Epub ahead of print].
- Ramaiahgari SC, den Braver MW, Herpers B, Terpstra V, Commandeur JN, van de Water B, et al. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. *Arch Toxicol.* 2014; 88:1083-95.
- Rodrigues AV, Rollison HE, Martin S, Sarda S, Schulz-Utermoehl T, Stahl S, et al. In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid. *Arch Toxicol.* 2013; 87:1569-79.
- Schug M, Heise T, Bauer A, Storm D, Blaszkewicz M, Bedawy E, et al. Primary rat hepatocytes as in vitro system for gene expression studies: comparison of sandwich, Matrigel and 2D cultures. *Arch Toxicol.* 2008;82:923-31.
- Schug M, Stöber R, Heise T, Mielke H, Gundert-Remy U, Godoy P, et al. Pharmacokinetics explain in vivo/in vitro discrepancies of carcinogen-induced gene expression alterations in rat liver and cultivated hepatocytes. *Arch Toxicol.* 2013;87:337-45.
- Schyschka L, Sánchez JJ, Wang Z, Burkhardt B, Müller-Vieira U, Zeilinger K, et al. Hepatic 3D cultures but not 2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity. *Arch Toxicol.* 2013;87:1581-93.
- Stern M, Gierse A, Tan S, Bicker G. Human Ntera2 cells as a predictive in vitro test system for developmental neurotoxicity. *Arch Toxicol.* 2014;88:127-36.
- Sung JH, Srinivasan B, Esch MB, McLamb WT, Bernabini C, Shuler ML, et al. Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure. *Exp Biol Med (Maywood).* 2014; 239:1225-39.
- Teichmann M, Kretschy N, Kopf S, Jarukamjorn K, Atanasov AG, Viola K, et al. Inhibition of tumour spheroid-induced prometastatic intravasation gates in the lymph endothelial cell barrier by carbamazepine: drug testing in a 3D model. *Arch Toxicol.* 2014;88: 691-9.
- Watzek N, Scherbl D, Schug M, Hengstler JG, Baum M, Habermeyer M, et al. Toxicokinetics of acrylamide in primary rat hepatocytes: coupling to glutathione is faster than conversion to glycidamide. *Arch Toxicol.* 2013;87:1545-56.
- Weis JM, Staicu SA, Chase KS. Lung-on-a-chip microdevice, right ventricular dysfunction as a predictor of survival, and lung ultrasound in community-acquired pneumonia. *Am J Respir Crit Care Med.* 2013;188:1028-9.
- Williamson A, Singh S, Fernekorn U, Schober A. The future of the patient-specific Body-on-a-chip. *Lab Chip.* 2013;13:3471-80.
- Xie Y, Hardouin P, Zhu Z, Tang T, Dai K, Lu J. Three-dimensional flow perfusion culture system for stem cell proliferation inside the critical-size beta-tricalcium phosphate scaffold. *Tissue Eng.* 2006;12: 3535-43.
- Zimmer B, Pallocca G, Dreser N, Foerster S, Waldmann T, Westerhout J, et al. Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery. *Arch Toxicol.* 2014;88:1109-26.
- Zweigerdt R, Gruh I, Martin U. Your heart on a chip: iPSC-based modeling of Barth-syndrome-associated cardiomyopathy. *Cell Stem Cell.* 2014;15:9-11.